- Home
- UPC vs MYNZ Comparison
UPC vs MYNZ Comparison
Compare UPC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPC
- MYNZ
- Stock Information
- Founded
- UPC 1998
- MYNZ 2021
- Country
- UPC China
- MYNZ Germany
- Employees
- UPC N/A
- MYNZ N/A
- Industry
- UPC Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- UPC Health Care
- MYNZ Health Care
- Exchange
- UPC Nasdaq
- MYNZ Nasdaq
- Market Cap
- UPC 2.2M
- MYNZ 5.5M
- IPO Year
- UPC 2021
- MYNZ 2021
- Fundamental
- Price
- UPC $3.76
- MYNZ $1.40
- Analyst Decision
- UPC
- MYNZ Buy
- Analyst Count
- UPC 0
- MYNZ 2
- Target Price
- UPC N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- UPC 70.0K
- MYNZ 120.1K
- Earning Date
- UPC 07-11-2025
- MYNZ 07-07-2025
- Dividend Yield
- UPC N/A
- MYNZ N/A
- EPS Growth
- UPC N/A
- MYNZ N/A
- EPS
- UPC N/A
- MYNZ N/A
- Revenue
- UPC $23,024,458.00
- MYNZ $893,991.00
- Revenue This Year
- UPC N/A
- MYNZ $26.06
- Revenue Next Year
- UPC N/A
- MYNZ $4.97
- P/E Ratio
- UPC N/A
- MYNZ N/A
- Revenue Growth
- UPC N/A
- MYNZ N/A
- 52 Week Low
- UPC $2.51
- MYNZ $1.34
- 52 Week High
- UPC $2,592.00
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- UPC 41.11
- MYNZ 23.25
- Support Level
- UPC $3.45
- MYNZ $1.34
- Resistance Level
- UPC $4.10
- MYNZ $1.48
- Average True Range (ATR)
- UPC 0.23
- MYNZ 0.13
- MACD
- UPC -0.03
- MYNZ -0.01
- Stochastic Oscillator
- UPC 37.78
- MYNZ 3.72
About UPC Universe Pharmaceuticals Inc.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.